2. Dezember 2022 – Moderna Switzerland GmbH has submitted an application to Swissmedic for authorisation of a further bivalent COVID-19 vaccine. The ready-to-use dispersion for injection contains both messenger RNA (mRNA) from the original Moderna COVID-19 vaccine (Spikevax) and mRNA coding for the spike protein of Omicron variants BA.4 and BA.5.

For more information, see here.